Sarcomatoid hepatocellular carcinoma in a chronic hepatitis B infection patient without previous antitumor therapy: a case report and literature review
Author:
Chen Xiaorong1, Luo Fang1, Zhou Hang2
Affiliation:
1. The First Affiliated Hospital of Chongqing Medical University 2. Jinshan Hospital, The First Affiliated Hospital of Chongqing Medical University
Abstract
Abstract
Background
Sarcomatoid hepatocellular carcinoma (SHC) is rare. As a subtype of hepatocellular carcinoma (HCC), the clinical manifestations of SHC are similar to those of traditional HCC. Surgical resection is the main treatment, and postoperative adjuvant therapy can prolong the life of patients. However, the prognosis of sarcomatoid hepatocellular carcinoma is worse than that traditional HCC.
Case presentation:
we report a 69-year-old male patient with sarcomatoid hepatocellular carcinoma who was admitted to the hospital because of liver enlargement. Abdominal computed tomography revealed a mass in the right lobe of the liver (6.8 cm*4.8 cm). After middle hepatectomy, sarcomatous hepatocellular carcinoma was confirmed by histopathology and immunohistochemistry, and the patient was treated with transcatheter arterial chemoembolization(TACE) and targeted drugs after surgery. The patient died 26 months after surgery. Furthermore, we summarized the clinical, pathological, imaging and treatment of this type of tumor to further understand this solid tumor.
Conclusion
Sarcomatoid hepatocellular carcinoma is a rare subtype of hepatocellular carcinoma, Immunohistopathology is the main way to confirm the diagnosis. Due to the high malignancy and recurrence and metastasis rates of SHC, definite pathological diagnosis, suitable postoperative adjuvant therapy and strict follow-up management are helpful to improve the progression-free survival and survival rate of patients with SHC.
Publisher
Research Square Platform LLC
Reference28 articles.
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87–108. doi: 10.3322/caac.21262. Epub 2015 Feb 4. PMID: 25651787. 2. Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, Li X, Wang L, Wang L, Liu Y, Liu J, Zhang M, Qi J, Yu S, Afshin A, Gakidou E, Glenn S, Krish VS, Miller-Petrie MK, Mountjoy-Venning WC, Mullany EC, Redford SB, Liu H, Naghavi M, Hay SI, Wang L, Murray CJL, Liang X. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019 Sep 28;394(10204):1145–1158. doi: 10.1016/S0140-6736(19)30427-1. Epub 2019 Jun 24. Erratum in: Lancet. 2020 Jul 4;396(10243):26. PMID: 31248666; PMCID: PMC6891889. 3. Villanueva A, Hepatocellular Carcinoma N, Engl JM. 2019 Apr 11;380(15):1450–1462. doi: 10.1056/NEJMra1713263. PMID: 30970190. 4. Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ, Weir HK. Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival. J Natl Cancer Inst. 2017 Sep 1;109(9):djx030. doi: 10.1093/jnci/djx030. PMID: 28376154; PMCID: PMC5409140. 5. Nishi H, Taguchi K, Asayama Y, Aishima S, Sugimachi K, Nawata H, Tsuneyoshi M. Sarcomatous hepatocellular carcinoma: a special reference to ordinary hepatocellular carcinoma. J Gastroenterol Hepatol. 2003 Apr;18(4):415 – 23. doi: 10.1046/j.1440-1746.2003.02888. x. PMID: 12653890.
|
|